Berlin

The trials here

What the 44 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia5 trials
• Coronary artery disease3 trials
• Familial hypercholesterolaemia3 trials
• High blood pressure3 trials
• Metastatic breast cancer3 trials
• Multiple sclerosis3 trials
• Chronic spontaneous urticaria2 trials
• Heart failure2 trials
• Hidradenitis suppurativa2 trials
• Macular degeneration2 trials
• Prostate cancer2 trials
• Pulmonary arterial hypertension2 trials
• and 16 more

Phase

• Phase 213 trials
• Phase 313 trials
• Phase 13 trials
• Phase 42 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed22 trials
• Active, not recruiting9 trials
• Recruiting8 trials
• Terminated5 trials

Lead sponsor

• Novartis Pharmaceuticals44 trials

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

  NCT07549516· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

  NCT07235059· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT07220577· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

  NCT06934967· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

  NCT07217067· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

  NCT06531499· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

  NCT06551519· Novartis Pharmaceuticals· Source

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany

  NCT06991608· Novartis Pharmaceuticals· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

  NCT05921994· Novartis Pharmaceuticals· Source

• Recruiting

  A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

  NCT05344469· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

  NCT03814746· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• High blood pressure1 recruiting
• Prostate cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

  NCT06004453· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

  NCT05763875· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

  NCT05566756· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

  NCT05135000· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

  NCT05362903· Novartis Pharmaceuticals· Source

• Completed

  A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

  NCT05032157· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

  NCT04948333· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

  NCT04679935· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

  NCT04632927· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

  NCT04543331· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

  NCT04150029· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

  NCT04179175· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

  NCT03822468· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

  NCT03656562· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

  NCT03574545· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

  NCT06311383· Novartis Pharmaceuticals· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

  NCT01698905· Phase 2· Novartis Pharmaceuticals· Source